Agenus Inc. (AGEN)
NASDAQ: AGENHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
AGEN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $341.88M
- P/E (TTM)
- 2.99
- EPS (TTM)
- $2.53
- Dividend yield
- None
- 52-week range
- 2.71 – 10.31
- Day range
- 7.27 – 7.62
- Volume / Avg
- 1.15M / 4.25M
- Beta
- —
- Shares outstanding
- 45.16M
52-week range
AGEN stock today
Shares of Agenus (AGEN) finished higher on Oct 7 at $7.57, a gain of 1.07% or $0.08 per share, versus the S&P 500's 0.22% decline. Trading was light, with 1.15M shares changing hands, about 27% of the average daily volume. Shares are 26.6% below their 52-week high of $10.31, set on Sep 30, 2026 and 179.3% above the 52-week low of $2.71, in the middle of the past year's range.
AGEN is up 141.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 78.1%. Agenus trades at 3.0x its trailing twelve-month earnings per share of $2.53.
Summary generated from market data by MetaCap's automated system. Methodology
About Agenus
Company profileAgenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Garo H. Armen Ph.D.
- Headquarters
- Lexington, MA
- Employees
- 81
- IPO year
- 2000
- Website
- agenusbio.com
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$26.33+247.82%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Agenus peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OCGNOcugen Inc. | 1.00 | -3.85% | $339.11M | vs AGEN |
| OBIOOrchestra BioMed Holdings Inc. | 5.66 | -3.08% | $340.19M | vs AGEN |
| ARTVArtiva Biotherapeutics Inc. | 7.00 | -3.71% | $342.23M | vs AGEN |
| CABACabaletta Bio Inc. | 1.97 | -2.48% | $334.00M | vs AGEN |
| SCTXScribe Therapeutics Inc. | 17.57 | +7.59% | $332.63M | vs AGEN |
| RLMDRelmada Therapeutics Inc. | 3.25 | -0.91% | $346.68M | vs AGEN |
| CCCCC4 Therapeutics Inc. | 2.82 | -2.08% | $346.93M | vs AGEN |
| ENTAEnanta Pharmaceuticals Inc. | 12.37 | +1.64% | $360.28M | vs AGEN |
Indexes, lists and sector
Appears in lists
Agenus stock FAQ
What is Agenus's stock price today?
AGEN last traded at $7.57 as of Oct 7, 4:00 PM EDT, up 1.07% on the day. Prices are delayed at least 15 minutes.
Does Agenus pay a dividend?
No. Agenus does not currently pay a regular cash dividend.
What is AGEN's P/E ratio?
AGEN trades at a trailing P/E ratio of 2.99.
Who is Agenus's CEO?
Dr. Garo H. Armen Ph.D. is the chief executive officer of Agenus Inc., which has about 81 employees.
Has AGEN ever split its stock?
Yes. The most recent AGEN stock split was a 1-for-20 split on Apr 12, 2024, one of 3 splits on record.
What is the AGEN 52-week high?
The 52-week high for AGEN is $10.31 and the 52-week low is $2.71. The stock is currently 26.6% below its high.